2-tert-butylthiazolo<4,5-b>pyridine | 173278-49-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-tert-butylthiazolo<4,5-b>pyridine
• 英文别名: 2-tert-butylthiazolo[4,5-b]pyridine；2-t-Butylthiazolo[4,5-b]pyridine；2-tert-butyl-[1,3]thiazolo[4,5-b]pyridine
• CAS: 173278-49-4
• 化学式: C₁₀H₁₂N₂S
• 分子量: 192.285
• InChiKey: OUGZEAGIFJIRQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-tert-butylthiazolo<4,5-b>pyridine 在 sodium hydroxide 、 硫酸 、 sodium methylate 、 肼 、 sodium nitrite 作用下， 以 乙醇 、 水 为溶剂， 反应 107.0h， 生成 2,6-diazaphenoxanthiine 2-oxide
  参考文献：
  名称：

  First Synthesis of 3-Mercapto-2(1H)-pyridinone, a Simple Disubstituted Pyridine Useful for Synthesis of the 4-Azaphenoxathiine Ring System and Its Novel Diazaphenoxathiine Analogs:  1,6-Diazaphenoxathiine and 2,6-Diazaphenoxathiine¹

  摘要：

  3-Mercapto-2(1H)-pyridinone (1) can be synthesized in three simple high-yielding steps from readily available 2-tert-butylthiazolo[4,5-b]pyridine (2). Its disodium salt condenses with o-chloronitrobenzene, 2-chloro-3-nitropyridine, and 3-chloro-4-nitropyridine 1-oxide to give respectively 4-azaphenoxathiine (10), 1,6-diazaphenoxathiine (12), and 2,6-diazaphenoxathiine 2-oxide (14) which reduces to 2,6-diazaphenoxathiine (15). The structures of these previously unreported azaphenoxathiine systems were confirmed by assignment of their respective C-13 NMR spectra.

  DOI：

  10.1021/jo951254j
• 作为产物：
  描述：

  2-amino-3-(diisopropyldithiocarbamato)pyridine 、 三甲基乙酸 在 三氯氧磷 作用下， 反应 4.0h， 以66%的产率得到2-tert-butylthiazolo<4,5-b>pyridine
  参考文献：
  名称：

  A Convenient Procedure for the Formation of 2-Substituted Thiazolopyridines

  摘要：

  2-Substituted thiazolo[4,5-b]pyridines and thiazolo[5,4-c]pyridines are prepared in reasonable yields by a procedure involving reaction of a mixture of ortho-amino (diisopropyldithiocarbamato) pyridine, carboxylic acid, and phosphorus oxychloride. The procedure provides a more convenient route than methods involving prior formation and isolation of the acid amide and cyclisation to give the desired product. The procedure is proven to be general for a wide range of substituents.

  DOI：

  10.1007/s00706-002-0557-9

文献信息

• VIRAL REPLICATION INHIBITORS
  申请人：KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D

  公开号：US20140213586A1

  公开（公告）日：2014-07-31

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新化合物，使用这些新化合物预防或治疗动物的病毒感染的方法，以及这些新化合物的药物用途，更好地用于治疗或预防病毒感染，特别是RNA病毒感染，更特别是属于黄病毒科的病毒感染，更进一步地是登革热病毒感染。本发明还涉及新化合物的药物组成物或复合制剂，以及用于预防或治疗病毒感染的药物组成物或制剂。本发明还涉及化合物的制备方法。
• PRMT5 INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20140221345A1

  公开（公告）日：2014-08-07

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了式(I)的化合物、其药学上可接受的盐以及其药物组合物。本发明的化合物可用于抑制PRMT5活性。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。
• TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF
  申请人：EPIZYME, INC.

  公开号：US20150344434A1

  公开（公告）日：2015-12-03

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5 mediated disorders are also described.

  本文描述了公式（A）的化合物，其药学上可接受的盐以及它们的药物组合物。本发明的化合物对于抑制PRMT5活性是有用的。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。
• PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF
  申请人：EPIZYME, INC.

  公开号：US20150344433A1

  公开（公告）日：2015-12-03

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了公式（A）的化合物，其药学上可接受的盐和药物组合物。本发明的化合物可用于抑制PRMT5活性。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。
• Glycosidase inhibitors
  申请人：Asceneuron SA

  公开号：US10336775B2

  公开（公告）日：2019-07-02

  The disclosure relates to compounds of formula (I) useful in the treatment of tauopathies and Alzheimer's disease wherein A, R, W, Q, n, and m are described herein.

  本公开涉及有助于治疗牛磺酸病和阿尔茨海默病的式（I）化合物 其中 A、R、W、Q、n 和 m 如本文所述。